Paweł Gut

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls

Paweł Gut, Agata Czarnywojtek, Jakub Fischbach et al. · Archives of Medical Science · 2016 · 138 citations · Full text

Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience

Jolanta Kunikowska, Anna Zemczak, Maciej Kołodziej et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 53 citations · Full text

The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population

Marta Kaczmarek-Ryś, Katarzyna Ziemnicka, Szymon Hryhorowicz et al. · Hereditary Cancer in Clinical Practice · 2015 · 36 citations · Full text

Growth hormone–secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report

Joanna Waligórska‐Stachura, Paweł Gut, Nadia Sawicka‐Gutaj et al. · Journal of neurosurgery · 2015 · 36 citations · Full text

Surgical Oncology, Human Growth, Pathology +19

A prospective randomized trial: A comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic Castrate Resistance prostate cancer (m

Maciej Bączyk, Piotr Milecki, Marcin Pisarek et al. · Neoplasma · 2013 · 31 citations

Pain Medicine, Pharmacotherapy, Radioisotope Treatment +16